<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sylvester, Bruce</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Teo, Koon</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Mixed Results with Telmisartan in ACE-Intolerant Patients with Diabetes or High-Risk Vascular Disease</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-16</style></pages><abstract><style  face="normal" font="default" size="100%">Telmisartan did not reduce the primary composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure in patients with diabetes or high-risk vascular disease who are unable to tolerate standard treatment with angiotensin-converting enzyme inhibitors, according to findings from the Telmisartan Randomized AssessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease [TRANSCEND; NCT00153101] Trial.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>